儿童镰状细胞视网膜病变的患病率与发病年龄
这项回顾性队列研究纳入398名镰状细胞血红蛋白病患儿,发现12.1%存在镰状细胞视网膜病变,其中非增殖型占11.1%、增殖型占2.3%;SC基因型患病率高于SS型且发病更早,疾病严重度临床标志物与视网膜病变无关。
要点
- 398名患儿中12.1%有视网膜病变,非增殖型11.1%、增殖型2.3%。
- SC型非增殖型患病率21%高于SS型9%,增殖型5%高于1%。
- SC型非增殖型最早诊断4.8岁早于SS型6.1岁,增殖型12.2岁早于15.4岁。
核心结论
- 镰状细胞血红蛋白病患儿中视网膜病变并不少见,SC基因型患病率更高且发病更早。
- 评估的疾病严重度临床标志物与视网膜病变无显著关联,不建议作为筛查依据。
研究设计与样本
- 回顾性队列研究,纳入4年期间398名镰状细胞血红蛋白病患儿,平均年龄9.6±4.6岁,范围0-18岁。
主要发现
- 非增殖型视网膜病变44/398名(11.1%,95%CI 8.3%-14.5%)。
- 增殖型视网膜病变9/398名(2.3%,95%CI 1.2%-4.2%)。
- SC型与SS型非增殖型患病率分别为21%与9%,增殖型分别为5%与1%。
- SC型非增殖型最早诊断年龄4.8岁早于SS型6.1岁,增殖型12.2岁早于15.4岁。
关键数值与推荐
- 基于本研究与文献复习,非增殖型视网膜病变筛查可从5岁开始。
- 无症状患儿以发现需治疗的增殖型视网膜病变为目的的筛查,SC型可自9岁开始、SS型可自13岁开始。
临床怎么用
- 对镰状细胞血红蛋白病患儿可按基因型分层安排眼底筛查起始年龄,SC型早于SS型。
- 疾病严重度临床标志物无需纳入筛查决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Children with sickle cell hemoglobinopathy (SCH) can demonstrate proliferative retinopathy with vision loss, but lack of consensus exists regarding screening regimens. We sought to determine the prevalence, age at onset, and risk factors associated with sickle cell retinopathy (SCR) to inform development of screening guidelines for asymptomatic children. DESIGN: Retrospective cohort study. PARTICIPANTS: Children with SCH over a 4-year period. METHODS: Prevalences of any retinopathy, nonproliferative retinopathy (NPR), and proliferative retinopathy (PR), determined as proportions of all children examined, were calculated. Subgroup analyses were completed by SCH genotype. Ages at first diagnosis were reported using standard descriptive statistics. The association of potential risk factors with retinopathy were assessed using univariate and multivariate linear and logistic regression. MAIN OUTCOME MEASURES: Outcomes were prevalence, age at onset, and type of SCR, based on examination by an ophthalmologist. Markers of SCH severity (number of emergency room or hospital admissions for crises, number of blood transfusions, hydroxyurea therapy, transcranial Doppler-confirmed cerebral vasculopathy), genotype, gender, and race were evaluated as SCR risk factors. RESULTS: Of 398 children (mean age, 9.6±4.6 years; range 0-18 years), 208 (52%) showed sickle cell homozygote (SS) genotype, 113 (28%) showed sickle cell hemoglobin C (SC) genotype, and 77 (19%) showed trait genotype. Forty-eight children (12.1%) demonstrated SCR, 44 of 398 children (11.1%; 95% confidence interval, 8.3%-14.5%) demonstrated NPR, and 9 of 398 children (2.3%; 95% confidence interval, 1.2%-4.2%) demonstrated PR. Prevalence was higher for SC than SS genotype for NPR (21% vs. 9%) and PR (5% vs. 1%); onset for SC genotype was earlier than that for SS genotype for NPR (youngest diagnosis 4.8 vs. 6.1 years) and PR (12.2 vs. 15.4 years). No other risk factors were associated significantly with SCR. CONCLUSIONS: Clinical markers of SCH severity assessed were not associated with SCR and are not necessary for screening guidelines. Based on our study and literature review, although screening could begin at age 5 years for NPR, screening of children without ophthalmologic symptoms to identify treatment-requiring PR could begin later, at 9 years of age for SC and 13 years of age for SS.
引用
- Li J, Bender L, Shaffer J, et al. Prevalence and Onset of Pediatric Sickle Cell Retinopathy. Ophthalmology. 2019. PMID: 30831194. doi:10.1016/j.ophtha.2019.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。